| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| Other Sizes |
| Targets |
As a protected amino acid intermediate, H-DL-Glu(OMe)-OMe.HCl does not possess a direct biological target. However, glutamic acid itself is a key neurotransmitter acting on NMDA, AMPA, and kainate receptors. When incorporated into peptides and deprotected, the glutamic acid residue can interact with these targets or serve as a metal-chelating group. As a synthetic intermediate, it is classified as a Glutamic Acid Derivative with no defined primary target.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The compound has no direct in vitro biological activity. It is used exclusively as a synthetic building block, not as a bioactive agent. No IC50, EC50, or cytotoxicity data are available. It may be used in enzymatic assays studying glutamic acid decarboxylase or glutaminase as a substrate or inhibitor only after deprotection to free glutamic acid. |
| ln Vivo |
No in vivo activity data are available. H-DL-Glu(OMe)-OMe.HCl is not administered to animals for efficacy. Peptides or drug candidates synthesized using this intermediate may be evaluated in animal models (e.g., glutamate-related neurological disorders), but no such data exist for the building block itself.
|
| Enzyme Assay |
The compound is not used in direct enzyme/receptor binding assays. For chemical analysis, standard HPLC with C18 column, UV detection at 210 nm, mobile phase water/acetonitrile (with 0.1% TFA) is used. For structural confirmation, ¹H NMR (DMSO-d₆) and mass spectrometry (ESI-MS) are standard. Solubility testing: soluble in DMSO and water (due to HCl salt). No biological binding assays are reported.
|
| Cell Assay |
No cell-based protocols are established for this protected glutamate. For downstream peptide synthesis: In solution-phase synthesis, H-DL-Glu(OMe)-OMe.HCl is neutralized with N-methylmorpholine or triethylamine (1.0 eq) in DMF or DCM. It is then coupled with an N-protected amino acid (Boc- or Fmoc-) using HOBt/DCC or HATU. After deprotection of the N-terminus, further elongation yields the desired peptide. The intermediate is not used in cell culture.
|
| Animal Protocol |
No animal experiments have been performed with H-DL-Glu(OMe)-OMe.HCl. For glutamate-containing peptides derived from this intermediate, typical in vivo studies might involve administration to mice or rats (intraperitoneal or intravenous) to assess neuroactivity, memory enhancement, or neurotoxicity. No data exist for the parent building block.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data are available for this compound. As a small MW (211.64) polar diester, if administered, the methyl esters would be rapidly hydrolyzed by esterases to yield free DL-glutamic acid. Free glutamic acid is cleared rapidly via normal amino acid metabolism and may be neuroexcitatory if levels rise. No ADME studies (half-life, bioavailability, clearance) have been reported. Soluble in DMSO and water.
|
| Toxicity/Toxicokinetics |
The safety profile: May cause skin and eye irritation. Harmful if swallowed (oral LD50 >2000 mg/kg predicted). Inhalation of dust may cause respiratory irritation. Not classified as carcinogen or reproductive toxin. Use standard laboratory PPE (gloves, goggles, lab coat, fume hood). Stable as a powder at -20degC for 3 years; in solution at -20degC for up to 6 months.
|
| References | |
| Additional Infomation |
H-DL-Glu(OMe)-OMe.HCl is not a drug and has no clinical trial or regulatory approval. It is a research chemical for peptide synthesis and medicinal chemistry. It is commonly used in the synthesis of glutamate-containing peptides, including neuromodulatory peptides, antibiotic analogs, and antitumor agents. The racemic (DL) mixture is useful for studying chirality effects in biological systems and for developing chiral separation methods. No approved drugs contain this specific protected building block; it is deprotected during synthesis. It is commercially available for research use only.
|
| Molecular Formula |
C7H14CLNO4
|
|---|---|
| Molecular Weight |
211.64
|
| Exact Mass |
211.061
|
| CAS # |
13515-99-6
|
| PubChem CID |
3084392
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
224.3ºC at 760 mmHg
|
| Melting Point |
154ºC
|
| Flash Point |
76.7ºC
|
| Vapour Pressure |
0.0919mmHg at 25°C
|
| LogP |
0.942
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
13
|
| Complexity |
169
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC(=O)CCC(C(=O)OC)N.Cl
|
| InChi Key |
MFUPLHQOVIUESQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H13NO4.ClH/c1-11-6(9)4-3-5(8)7(10)12-2;/h5H,3-4,8H2,1-2H3;1H
|
| Chemical Name |
dimethyl 2-aminopentanedioate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7250 mL | 23.6250 mL | 47.2500 mL | |
| 5 mM | 0.9450 mL | 4.7250 mL | 9.4500 mL | |
| 10 mM | 0.4725 mL | 2.3625 mL | 4.7250 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
